98%
921
2 minutes
20
Recently, several comprehensive genomic analyses demonstrated and mutations in head and neck squamous cell carcinoma (HNSCC) in approximately 20% of cases. Similar to other types of cancers, these studies also indicate that the pathway is closely related to HNSCC progression. However, the role of in HNSCC is less well understood. We analyzed pathway and downstream gene expression in the TCGA data set. To explore the functional role of , we performed proliferation, cisplatin viability, apoptosis, and cell-cycle assays. We also compared the relationships among , and epithelial-mesenchymal transition (EMT)-related genes using the TCGA data set and assays. is specifically upregulated in HNSCC compared with normal tissues in the TCGA data set. is more significantly related to activation in HNSCC in comparison with other receptors. promotes cell proliferation, cisplatin resistance, inhibition of apoptosis, and cell-cycle dysregulation. Furthermore, and upregulation resulted in decreased expression and increased , and expression. and expression was associated with an EMT phenotype as well as increased invasion and cell migration. In HNSCC, the pathway is specifically upregulated, induces proliferation and cisplatin resistance, and promotes EMT. .
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171749 | PMC |
http://dx.doi.org/10.1158/1078-0432.CCR-17-1366 | DOI Listing |
Urol Oncol
September 2025
Nutritional, Genes and Human Disease Laboratory, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh. Electronic address:
Background: Understanding the mutational landscape is critical for elucidating the molecular mechanisms driving cancer progression. This study aimed to profile somatic mutations in bladder cancer patients (N=7) from Bangladesh to provide insights into the genetic alterations underlying this malignancy.
Methods: We performed targeted sequencing of 50 oncogenes and tumor suppressor genes using the Ion AmpliSeq Cancer Hotspot Panel v2 on tumor and matched blood samples from seven bladder cancer patients.
Front Immunol
September 2025
Department of Medicine, Division of Hematology, Bioclinicum and Center for Molecular Medicine, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden.
Background: Metabolic reprogramming is an important hallmark of cervical cancer (CC), and extensive studies have provided important information for translational and clinical oncology. Here we sought to determine metabolic association with molecular aberrations, telomere maintenance and outcomes in CC.
Methods: RNA sequencing data from TCGA cohort of CC was analyzed for their metabolic gene expression profile and consensus clustering was then performed to classify tumors into different groups/subtypes.
Front Genet
August 2025
Department of Gastrointestinal and Hernia Surgery, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, China.
Background: Gastric cancer (GC) is a leading cause of cancer-related mortality; however, biomarkers predicting its immunotherapy resistance remain scarce. Vascular cell adhesion molecule ()-, an immune cell adhesion mediator, is implicated in tumor progression; however, its prognostic and immunomodulatory roles in GC remain unclear.
Methods: In this study, we analyzed expression and its clinical relevance in GC using RNA-sequencing data from The Cancer Genome Atlas.
Front Cell Dev Biol
August 2025
Department of Hepatobiliary Surgery, The First Hospital of Putian City, Chengxiang, Fujian, China.
Background: USP37, a versatile deubiquitinase, plays a pivotal role in numerous cellular functions. Although its involvement in cancer development is well-established, the comprehensive pan-cancer analysis of USP37 remains relatively uncharted.
Methods: RNA sequencing data from both normal and cancerous tissues were retrieved from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases.
Curr Gene Ther
September 2025
Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, Jiangsu, China.
Introduction: Pancreatic Cancer (PC) is recognized as a highly aggressive malignancy and is anticipated to become the second leading cause of cancer-associated deaths across the United States by 2030. Owing to its late-stage diagnosis and the substantial risk of metastasis, current therapeutic strategies exhibit limited efficacy, resulting in a five-year survival rate below 10%. Consequently, identifying reliable biomarkers and therapeutic approaches remains imperative for enhancing treatment effectiveness.
View Article and Find Full Text PDF